AbbVie Inc. (NYSE:ABBV)’s experimental blood-cancer therapy etentamig delivered positive results in a late-stage trial for patients with relapsed or refractory multiple myeloma, meeting the trial’s main objectives. The drug produced an objective response rate of 74%, compared with 45.7% for standard treatments selected by investigators. More importantly, etentamig reduced the risk of disease progression or death by 60% in the 393-patient study. At 12 months, 87.9% of patients receiving etentamig were alive versus 72% among those receiving standard treatment.
The results are particularly relevant because AbbVie is looking to oncology and other newer therapeutic areas to offset pressure from the loss of Humira exclusivity and build longer-term growth around newer drugs such as Skyrizi and Rinvoq.
Strengthening the Oncology Opportunity
The strongest bullish argument is that etentamig could give AbbVie Inc. a meaningful new growth opportunity in oncology. A 74% response rate and a 60% reduction in the risk of progression or death represent clinically significant results in a difficult-to-treat multiple myeloma population that had already received a median of three prior lines of therapy.
The drug could also have a commercial positioning advantage. Citi analyst Geoffrey Meacham said etentamig appears particularly differentiated as a treatment used after CAR-T therapy rather than necessarily replacing existing CAR-T products. Unlike CAR-T, which can require complex treatment processes, etentamig offers immediate availability and monthly administration, potentially allowing it to reach a broader group of treatment centers.
The positive trial therefore strengthens the argument that AbbVie Inc. can build a more diversified pharmaceutical portfolio beyond its legacy products. Success in oncology would give the company another potential source of revenue growth while its newer immunology franchises continue to expand. It also demonstrates that AbbVie’s investments in oncology are producing clinically meaningful pipeline assets rather than relying exclusively on acquisitions.
Commercial Hurdles Remain
Despite the encouraging results, etentamig is still not an immediate revenue contributor. AbbVie Inc. must progress through regulatory review and commercialization before the drug can materially affect earnings. The detailed trial results are also still expected to be presented at the International Myeloma Society meeting later this month, meaning investors do not yet have the complete dataset.
Competition is another significant risk. Etentamig is entering a highly competitive multiple myeloma market, where established therapies- including CAR-T treatments- already provide deep responses. Citi’s Meacham characterized etentamig as potentially more complementary to CAR-T than a direct replacement, which could limit its addressable market if physicians continue favoring competing therapies for appropriate patients.
There are also safety and tolerability considerations. Because etentamig activates T-cells, patients can experience cytokine release syndrome, an inflammatory immune reaction. Reuters reported that this occurred in 28.3% of patients receiving the dose-escalation regimen. Although fewer patients discontinued treatment because of adverse events, the safety profile will remain an important consideration for regulators, physicians and payers.
Most importantly for investors, the trial does not fundamentally resolve AbbVie’s broader growth question. Citi’s assessment was that the data improve AbbVie Inc.’s credibility in oncology but do not change the broader investment debate, with the performance of Skyrizi and Rinvoq and AbbVie’s ability to build its 2030s growth profile through additional transactions remaining critical.
Conclusion
Overall, the news is clearly positive for AbbVie Inc., but it is more strategically important than immediately transformational. Etentamig’s strong efficacy results provide AbbVie with a credible potential oncology growth engine and could establish the drug as a useful option for heavily pretreated multiple myeloma patients. However, competition, safety considerations, regulatory approval, and the drug’s eventual commercial positioning mean the financial payoff remains uncertain.
For investors, the key takeaway is that etentamig strengthens AbbVie’s long-term pipeline and diversification story, but Skyrizi, Rinvoq, and broader portfolio execution remain more important to the company’s near- to medium-term growth outlook. In other words, the trial removes a major question mark around etentamig’s clinical potential, but it does not by itself change the overall AbbVie investment thesis.
READ NEXT: Snowflake (SNOW)’s AI Push Strengthens its Growth Outlook and The Campbell’s Company (CPB) Braces for Pressure as Spending Weakens
This article is originally published at Insider Monkey.
Hedge Fund Resource Center